CVRx
NASDAQ: CVRXAustin, US · Founded 2001 · Delaware corporation · 261 employees on LinkedIn · 6 known investors
Find your way into CVRx
308 people in our graph share verified history with the CVRx team — schools, employers, funds. One of them is your warm intro.
John Carpenterunlockedknows Kevin Hykes · together at Northwestern University - Kellogg School of Management (overlapped)
knows the team · via Northwestern University - Kellogg School of Management
×7knows the team · via Versant Ventures
knows the team · via Wisconsin School of Business
×2knows the team · via CVRx
CVRx develops Barostim, an implantable medical device that uses baroreceptor activation to treat heart failure patients and improve their functional capacity and quality of life.
Founders & leadership
CP
Craig PalmerinCommercial Officer | Senior Vice President US Sales2022–2024Craig Palmer is Executive Officer at CVRx, which develops Barostim, an implantable medical device for heart failure treatment. He has experience creating clinical, commercial, and go-to-market strategies for therapeutic adoption.
NY
Nadim YaredinExecutive
DB
Dean Bruhn-DinginRetired
JB
John BrintnallinCFO2003–2022
LG
Liz GalleExecutive
KH
PB
Philip B. AdamsoninChief Medical OfficerPhilip B. Adamson is Chief Medical Officer of CVRx, which develops Barostim for heart failure treatment. Previously, he served as Divisional Vice President and Chief Medical Officer for Abbott's Heart Failure Division, with experience in clinical trial design, regulatory affairs, and reimbursement strategy across the US and international markets. He holds an MD and a Master of Science in Cardiovascular Physiology from the University of Oklahoma Health Sciences Center.
BB
Brent BinkowskiinChief Operating Officer
RJ
Robert JohninChief Revenue Officer (CRO)2024–2026Chief Revenue Officer of CVRx, which develops Barostim, an implantable medical device for heart failure treatment. Robert John has held commercial leadership roles and has experience in strategy, team building, and business operations.
GM
Greg MorrisoninChief Human Resources OfficerChief Human Resources Officer at CVRx, Greg Morrison has held HR leadership roles in both public and private companies focused on organizational development and management processes.
JO
Jared OasheimChief Financial Officer
PV
Paul VerrastroinChief Marketing Officer for CVRx_Inc.
Investors · 6
New Enterprise Associates (NEA)Menlo Park · $200K – $40Mvia Ali Behbahani · board
Treo Ventures, LlcMinneapolis
Windham Capital PartnersNew York · $1M – $5M
Ysios CapitalBarcelona · $5.4M – $21.6M
Hatteras Venture PartnersreportedResearch Triangle · $500K – $4M
Vensana Capitalreported · 2 sourcesMinneapolis
Reported raises · per SEC filings
Form D private placements$125.3M disclosed across 2 rounds · 2016–2020
▶$50MraisedJul 2020 · 21 investors · Other Health CareRule 506(b)
▶$50MraisedJul 2020 · 21 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- John BrintnallExecutive Officer
- Elizabeth GalleExecutive Officer
- Dean Bruhn-DingExecutive Officer
- Kirk NielsenDirector
- Ali BehbahaniDirector
- Kadir KadhiresanDirector
- Mudit K. JainDirector
- Joseph SlatteryDirector
- Nadim YaredExecutive Officer, Director
- Geoff PardoDirector
- John M. NehraDirector
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$75.3MraisedMay 2019 · 20 investors · Other Health CareRule 506(b)
▶$75.3MraisedMay 2019 · 20 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Craig PalmerExecutive Officer
- Geoff PardoDirector
- Nadim YaredExecutive Officer, Director
- Dean Bruhn-DingExecutive Officer
- John BrintnallExecutive Officer
- Liz GalleExecutive Officer
- John M. NehraDirector
- Kadir KadhiresanDirector
- Ali BehbahaniDirector
- Joseph SlatteryDirector
- Tom HeymanDirector
- Offering amount
- $93M
- Amount sold
- $75.3M
- First sale
- May 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$347.3Mvaluation at IPOJul 2021 · $18.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 1
by search overlap
Companies competing with CVRx for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does CVRx do?
- CVRx develops Barostim, an implantable medical device that uses baroreceptor activation to treat heart failure patients and improve their functional capacity and quality of life.
- Who are CVRx's investors?
- CVRx's investors include New Enterprise Associates (NEA), Treo Ventures, Llc, Windham Capital Partners, Ysios Capital, Hatteras Venture Partners, Vensana Capital.
- How much funding has CVRx raised?
- CVRx has disclosed $125.3M raised across 2 rounds.
- Where is CVRx headquartered?
- CVRx is headquartered in Austin, US.